.avif)
OVA1 Test - Ovarian Cancer Biomarker Panel
OVA1 is a blood-based multibiomarker test that assesses the likelihood that an ovarian/adnexal mass is malignant to help clinicians decide on specialist referral and surgical planning. By improving early detection and appropriate referral, it can help reduce the risk of delayed ovarian cancer diagnosis and worse outcomes.
Inhibin B Test - Ovarian Cancer Biomarker
The Inhibin B test measures the reproductive hormone inhibin B to evaluate ovarian reserve in women and spermatogenic/testicular function in men. Early identification of low inhibin B or hormonal imbalance can prompt timely fertility treatment and investigation of testicular or ovarian dysfunction, helping reduce the risk of delayed diagnosis and infertility.
AMH Test - Ovarian Cancer Biomarker
An AMH test measures your ovarian reserve to give a clear snapshot of your current fertility potential. Knowing your AMH can help you avoid surprises by identifying diminished ovarian reserve, early menopause risk, or signs of PCOS so you can pursue fertility preservation or targeted treatment sooner.
HE4 Test - Ovarian Cancer Biomarker
The HE4 test measures levels of the HE4 protein to help detect and monitor epithelial ovarian cancer and to assess whether a pelvic mass is more likely benign or malignant. Used alongside CA‑125 and risk algorithms, it may help catch ovarian cancer earlier or spot recurrence sooner, enabling timelier treatment and potentially reducing the chance of advanced‑stage disease.
CA-125 Test - Ovarian Cancer Biomarker
A CA‑125 blood test measures the level of the CA‑125 protein, a tumor marker most commonly used to help detect and monitor ovarian cancer. Identifying elevated or rising CA‑125 levels can prompt timely follow-up and treatment, potentially helping avoid delayed diagnosis or progression to more advanced disease.
.svg)
